Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare Biotechnology
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 12, 2025

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

GlobeNewswire May 5, 2025

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

GlobeNewswire May 1, 2025

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

GlobeNewswire April 9, 2025

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire April 1, 2025

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 5, 2025

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

GlobeNewswire February 26, 2025

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

GlobeNewswire February 20, 2025

Aquestive Therapeutics to Present New Findings on Anaphylm(TM) (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

GlobeNewswire February 12, 2025

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

GlobeNewswire February 4, 2025

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

GlobeNewswire January 13, 2025

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

GlobeNewswire December 19, 2024

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire December 2, 2024

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 12, 2024

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 4, 2024

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm(TM) (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

GlobeNewswire October 25, 2024

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire October 24, 2024

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

GlobeNewswire October 21, 2024

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

GlobeNewswire September 27, 2024

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

GlobeNewswire September 9, 2024